Results of studies

According to the results of international studies, Polyoxidonium is recognized as safe for all groups of patients and is included in the clinical recommendations not only in Russia, but also in Slovakia.

Randomized, placebo-controlled, double-blind clinical trials to evaluate efficacy and safety have shown that, in the therapy of ARVI, Polyoxidonium contributes to (2, 3, 4):

Decrease in the severity of the course of a disease
Decrease in the duration of clinical symptoms
Decrease in the risk of recurrences
Decrease in the need for long-term antibacterial therapy

Within a randomized, placebo-controlled, double-blind trial of Polyoxidonium, patients were monitored for 6 months. The trial included children with acute respiratory infections. During the study, no negative changes in their health condition were observed, which may indicate a high safety profile of the Polyoxidonium drug.

A meta-analysis of efficacy and safety clinical trials showed that, in the therapy of inflammatory infections of the respiratory tract, Polyoxidonium (5):

Reduces the period of the body temperature normalization
Reduces the duration of muscle and joint pain.
Reduces the duration of upper respiratory tract acute inflammation symptoms.
PASS study

In 2017, a PASS study (Post Authorisation Safety Study) — a multicenter, prospective, open-label, non-interventional, post-authorization safety study was completed in Europe (Slovakia) (6).

patients participated in the study
research centers
patients reported improvement during treatment

The safety profile was confirmed in all patient categories.

Polyoxidonium is included in methodological and clinical recommendations and is supported by leading scientific communities:
Why Polyoxidonium?
Polyoxidonium can increase reduced immune system parameters, decrease the high ones and has no effect on the normal parameters. No hyperactivation of the immune system takes place (7).
Polyoxidonium is compatible with many drugs, including antibiotics, antiviral drugs, cytostatic drugs and glucocorticosteroids, antihistaminic drugs (1).
ВHigh-tech manufacturing operates in full compliance with Russian and international standards. The company uses eco- and environmentally friendly technologies.
No accumulative, cumulative effect: the drug is completely eliminated from the body mainly by the kidneys. It is possible to repeat courses of therapy in 3–4 months (1).
It is a chemically pure drug and does not contain any antigens of animal or plant origin, so it can be used in people with allergic pathologies (1).
The positive 20-year experience of Polyoxidonium use in various therapeutic areas confirms its safety (1).
Learn more about the drug
  1. Instructions for medical use of the drug Polyoxidonium.
  2. S.M. Kharit, A.N. Galustyan. Azoximer bromide is a safe and effective drug in the treatment of acute upper respiratory tract infections in children: a review of the results of randomized, placebo-controlled, double-blind phase II and III clinical trials // Pediatrics (Consilium Medicum Journal Supplement). — 2017. — 2.
  3. T.I. Garaschenko, O.V. Karneeva, G.D.Tarasova et al. Influence of local application of Polyoxidonium on symptoms and course of acute respiratory viral infection in children: results of a multicenter, double-blind, placebo-controlled study. // Consilium Medicum. — 2020. — 22 (3). — Pages 80–86.
  4. V.S. Kharlamova, V.F. Uchaikin et al. Experience of the Polyoxidonium® immunomodulator use in treatment of ARI in children // Effective Pharmacotherapy. Epidemiology and Infections. — 2013. — No. 1(11). — Pages 12–20.
  5. A.V. Karaulov, A.V. Gorelov. The use of azoximer bromide in the therapy of inflammatory infections of the respiratory system in children: a meta-analysis of controlled clinical trials // Journal of Infectology. — Volume 11. — No. 4. — 2019. — Pages 31–41.
  6. P. Pruzhinets, N. Chirun, O. Sveikata. Safety profile of Polyoxidonium in daily practice: results of post-authorization safety study in Slovakia // Immunotherapy. — 2018. — 10 (2). — Pages 1–7.
  7. Letter from the Russian Association of Allergists and Clinical Immunologists on the Polyoxidonium drug use.
Asc a question
If you have a non-standard question, please contact us. Attention! Referring to the site is not a substitute for consulting a doctor.
* Required fields
Asc a question
The question has been successfully sent, we will contact you shortly.